Hunziker U A, Superti-Furga A, Zachmann M, Del Pozo E, Shmerling D, Prader A
Department of Paediatrics, University of Zurich, Switzerland.
Helv Paediatr Acta. 1988 Aug;43(1-2):103-9.
The long-acting somatostatin analogue SMS 201-995 was administered to a six-month-old infant with intractable diarrhea after failure of conventional treatment. During eight weeks of treatment, the secretory component of the diarrhea was positively influenced with a reduction of daily stool weight and stool sodium concentration. Plasma levels of growth hormone were markedly, and levels of insulin, IGF I, gastrin, pancreatic polypeptide, VIP, and neurotensin moderately decreased. Linear growth was also inhibited. The patient unexpectedly died from fulminant colitis at a time, when the dosage had been reduced from 18 to 3.5 micrograms/kg/day. The relationship, if any, between therapy with SMS 201-995 and the colitis remained unclear. It is concluded that SMS 201-995 can be effective in reducing secretory diarrhea in infants. However, further studies are necessary to assess the safety of its administration in this age group.
在常规治疗失败后，对一名患有顽固性腹泻的6个月大婴儿给予长效生长抑素类似物SMS 201-995。在治疗的8周内，腹泻的分泌成分受到积极影响，每日粪便重量和粪便钠浓度降低。生长激素的血浆水平显著降低，胰岛素、IGF-I、胃泌素、胰多肽、VIP和神经降压素的水平中度降低。线性生长也受到抑制。在剂量从18微克/千克/天降至3.5微克/千克/天的时候，该患者意外死于暴发性结肠炎。SMS 201-995治疗与结肠炎之间（如果存在）的关系仍不清楚。结论是，SMS 201-995可有效减少婴儿分泌性腹泻。然而，有必要进一步研究以评估在该年龄组给药的安全性。
